Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

a targeted bone and parathyroid hormone technology, applied in the direction of parathyroid hormones, drug compositions, peptide/protein ingredients, etc., can solve the problems of limiting the use of locally administered drugs, limiting the frequency of complicated and life-threatening fractures, and being a major burden to our health care system

Inactive Publication Date: 2020-10-08
PURDUE RES FOUND INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a compound that includes a parathyroid hormone receptor modulator and a bone-targeting molecule. The compound can enhance the activity of the parathyroid hormone receptors and has been found to be effective in treating bone-related disorders. The compound can be administered as a pharmaceutical or a pharmaceutical salt. The patent also describes a method of treating bone-related disorders using the compound.

Problems solved by technology

This alone is a major burden to our health care system.
This problem is compounded by the maturing baby boomer generation and a general aging population in much of the developed world, With baby boomers increasing the frequency of osteoporosis, the frequency of complicated and life-threatening fractures will dramatically increase.
Still, the FDA judiciously continues to limit approved use of locally administered drugs to fractures that are already open and at risk of infection.
This limitation necessitates a clinically relevant approach to treating these types of fractures.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
  • Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
  • Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

elivery System for Targeted Bone Fracture Healing

[0170]In this Example a fracture targeted pharmaceutical comprising a drug, a linker and a targeting ligand were synthesized.

[0171]The sequence of the pharmaceutical is listed in SEQ ID NO:10, which comprises amino acid residues 1-46 of PTHrP followed by 10-Aspartic acids. As described above, residues 1-34 are the active portion of PTHrP, residues 35-46 are the linker portion of the proposed pharmaceutical for healing bone fracture, and the 10-Aspartic acids are the targeting ligand.

[0172]The closed femoral fractures were produced in three groups of mice. Mice were dosed daily for 4 weeks with either targeted PTHrP (31 nmol / kg / day). PTHrP1-34 (31 nmol / kg / day) or saline. At the end of the study, mice were euthanized by CO2, femurs were harvested, and bone densities were determined by MicroCT.

[0173]As shown in FIG. 1, the targeted version of PTHrP increased bone densities around fractures significantly higher than that of free PTHrP and...

example 2

ifferent Combinations of Anabolic Drug with Linker Choices and Targeting Ligands to Make Targeted Delivery of the Drug to Bone Fracture for Healing

[0183]In this Example, the first 34 amino acid of PTH is synthesized with a suitable linker described herein and a suitable targeting ligand. Like in Example 1, the linker may be any segment of the extension of the active PTH, including residues 35-84, or other linkers described in Example 1. The targeting ligand may be any of those described in Example 1. As shown in FIG. 3, the linker is the amino acid residues 36-46 and the targeting ligand is 10 aspartic acid. The synthesized drug-linker-targeting ligand (PTH 1-46D10, SEQ ID NO:11) may be compared to the PTH variant itself and saline for their effect on bone densities around fractures. The targeted version of PTH variants is expected to increase bone densities around fracture significantly higher than that of free PTH variant and Saline. FIG. 3 has shown targeted PTH 1-46D10 is statis...

example 3

tide 1-34 as a Free Standing Bone Fracture Healing Agent

[0185]In this Example, Abaloparatide 1-34 with modified residues on 29 as Methyl Ala and on 34 as aminated Ala (SEQ ID NO:3) were tested. Abaloparatide has been tested treating osteoporosis to prevent fractures. Its ability to heal actual fractures is being tested, which is a different process. Of course, having Abaloparatide 1-34 linked to the linkers and targeting ligands described in previous Examples will likely increase the bone density at the fracture site, due to the targeted delivery.

[0186]Referring now to FIG. 1, a selection of 100 CT frames (slices) from each fracture callus were analyzed. CT frames were taken at 4 weeks. The stack of frames was chosen from the area of the fracture where the callus was the largest. From left to right the targeted PTHrP (PTHrP1-46 followed by 10 aspartic acids), free unconjugated PTHrP (PTHrP1-34), and saline control. The targeted version of PTHrP increased bone densities around fractu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and / or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite. This system offsets some side effects caused by free anabolic drug, such as high blood calcium concentration

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 62 / 428,492, filed Nov. 30, 2016, and U.S. Provisional Application No. 62 / 553,313, filed on Sep. 1, 2017, the entire disclosures of both of which are hereby expressly incorporated by reference herein.FIELD OF INVENTION[0002]Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases / symptoms induced by bone-related diseases. Embodiments include methods of treating a bone related disease, comprising the steps of: providing to a subject at least one therapeutically effective dose of a compound disclosed herein.BACKGROUND[0003]This section introduces aspects that may help facilitate a better understanding of the disclosure. These statements are to be read in this light and are not to be understood as admissions about what is or what is not prior art.[0004]Healthy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/635A61P19/08A61P19/10
CPCA61P19/10A61K38/00A61P19/08C07K14/635A61K31/197A61K31/663A61K47/548A61K47/645A61P5/18A61K2300/00A61K9/0014A61K9/0031A61K9/0053A61K38/29
Inventor LOW, PHILIP S.LOW, STEWART ANDREWENIELSEN, JEFFREY
Owner PURDUE RES FOUND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com